|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
CN100553625C
(zh)
|
2002-04-09 |
2009-10-28 |
弗拉梅技术公司 |
活性成分微囊的口服混悬液
|
|
JP2006516976A
(ja)
|
2003-01-13 |
2006-07-13 |
ダイノゲン ファーマシューティカルズ，インコーポレイテッド |
機能性腸障害を処置する方法
|
|
ATE487478T1
(de)
*
|
2003-01-30 |
2010-11-15 |
Lek Pharmaceuticals |
Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
|
|
AU2004208615C1
(en)
*
|
2003-01-31 |
2010-05-13 |
Daiichi Sankyo Company, Limited |
Medicine for prevention of and treatment for arteriosclerosis and hypertension
|
|
EP1750717B1
(en)
*
|
2004-02-11 |
2017-07-19 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
KR20070074576A
(ko)
*
|
2004-10-29 |
2007-07-12 |
코와 가부시키가이샤 |
사구체 질환 치료제
|
|
CA2598410A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
TWI405580B
(zh)
*
|
2005-06-27 |
2013-08-21 |
Sankyo Co |
含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
PL1919466T3
(pl)
|
2005-07-11 |
2012-05-31 |
Cortria Corp |
Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
AU2009223061B2
(en)
|
2008-03-11 |
2014-10-09 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
CN102065847A
(zh)
|
2008-04-29 |
2011-05-18 |
韩诺生物制约株式会社 |
含有血管紧张素-ⅱ受体阻断剂的药物制剂
|
|
TW201014850A
(en)
*
|
2008-09-25 |
2010-04-16 |
Takeda Pharmaceutical |
Solid pharmaceutical composition
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
US9744142B2
(en)
|
2009-05-05 |
2017-08-29 |
Board Of Regents, The University Of Texas Systems |
Formulations of volatile anesthetics and methods of use for reducing inflammation
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
WO2012021629A2
(en)
|
2010-08-11 |
2012-02-16 |
Philadelphia Health & Education Corporation |
Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
EA037918B1
(ru)
|
2011-12-21 |
2021-06-07 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
|
EP2846777B1
(en)
|
2012-05-07 |
2016-10-26 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
|
US9388126B2
(en)
|
2012-07-19 |
2016-07-12 |
Drexel University |
Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
ES2689906T3
(es)
|
2012-08-09 |
2018-11-16 |
Dynamis Therapeutics, Inc. |
Meglumina para reducir los niveles altos de triglicéridos
|
|
DK2941233T3
(da)
|
2013-01-07 |
2020-10-19 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
|
|
EP3878445A3
(en)
|
2013-06-05 |
2021-10-27 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
BR112015032961B1
(pt)
|
2013-07-02 |
2021-11-30 |
Ecoplanet Environmental Llc |
Formulação, e, métodos para tratar resíduos humanos ou animais e para eliminar ou reduzir crescimento microbiano em um local de tratamento
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
WO2015028972A1
(en)
|
2013-09-02 |
2015-03-05 |
Ranbaxy Laboratories Limited |
Pulsatile-release dosage form
|
|
US9908915B2
(en)
|
2013-11-26 |
2018-03-06 |
Yale University |
Cell-penetrating compositions and methods using same
|
|
AU2014360455B2
(en)
|
2013-12-06 |
2018-05-10 |
Genentech, Inc. |
Serine/threonine kinase inhibitors
|
|
WO2015089049A1
(en)
|
2013-12-09 |
2015-06-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
WO2015157262A1
(en)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2016028753A1
(en)
|
2014-08-20 |
2016-02-25 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
|
PL3298140T3
(pl)
|
2015-05-19 |
2024-11-12 |
Yale University |
Kompozycje do leczenia patologicznych stanów zwapnienia i sposoby ich stosowania
|
|
WO2016201288A1
(en)
|
2015-06-12 |
2016-12-15 |
Brown University |
Novel antibacterial compounds and methods of making and using same
|
|
EP3316890B1
(en)
|
2015-06-30 |
2023-09-06 |
Neurad Ltd. |
Novel breathing control modulating compounds, and methods of making and using same
|
|
CN108135886A
(zh)
*
|
2015-07-29 |
2018-06-08 |
塔科达有限责任公司 |
用于糖尿病性肾病治疗的pde4抑制剂
|
|
WO2017075145A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Quinoline amides and methods of using same
|
|
JP2018537093A
(ja)
|
2015-11-20 |
2018-12-20 |
イエール ユニバーシティ |
異所性石灰化障害を治療するための組成物およびそれを使用する方法
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
WO2018026764A1
(en)
|
2016-08-01 |
2018-02-08 |
University Of Rochester |
Nanoparticles for controlled release of anti-biofilm agents and methods of use
|
|
JP2019532915A
(ja)
|
2016-08-05 |
2019-11-14 |
イエール ユニバーシティ |
小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
|
|
WO2018045229A1
(en)
|
2016-09-01 |
2018-03-08 |
Mebias Discovery Llc |
Substituted ureas and methods of making and using same
|
|
US10821103B2
(en)
|
2016-11-07 |
2020-11-03 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing trycyclic compounds, and methods using same
|
|
EP3571196B1
(en)
|
2017-01-19 |
2023-01-04 |
Temple University Of The Commonwealth System Of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
US11166953B2
(en)
|
2017-04-17 |
2021-11-09 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|
|
CA3071345A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
Anticancer drugs and methods of making and using same
|
|
SG11202002060XA
(en)
|
2017-09-08 |
2020-04-29 |
Univ Colorado Regents |
Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
|
|
US20200323895A1
(en)
|
2017-11-27 |
2020-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
|
|
JP2021506984A
(ja)
|
2017-12-18 |
2021-02-22 |
トリス・フアルマ・インコーポレーテツド |
トリガーパルス薬物放出を有する胃内滞留型ｒａｆｔ形成システムを含む放出調節薬物粉末組成物
|
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
|
EP3737353A1
(en)
|
2017-12-18 |
2020-11-18 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019126216A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Phama, Inc. |
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
AU2019212241A1
(en)
|
2018-01-24 |
2020-08-13 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
EP3802572A4
(en)
|
2018-05-25 |
2022-03-23 |
Temple University - Of The Commonwealth System of Higher Education |
REMOVAL OF BACTERIAL BIOFILM USING ANTI-AMYLOID MONOCLONAL ANTIBODIES
|
|
KR20210015892A
(ko)
|
2018-05-29 |
2021-02-10 |
세르시 테라퓨틱스 인코포레이티드 |
통증 치료를 위한 화합물, 이를 포함하는 조성물 및 이를 사용하는 방법
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
AU2019321654B8
(en)
|
2018-08-17 |
2025-08-07 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of acute lung injury
|
|
WO2020074944A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
|
US12458601B2
(en)
|
2018-10-19 |
2025-11-04 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN113365636A
(zh)
|
2019-01-30 |
2021-09-07 |
萨尼菲特治疗有限公司 |
用于增加组织灌注的磷酸肌醇化合物
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
US10918700B2
(en)
|
2019-04-12 |
2021-02-16 |
Sdg, Inc. |
Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
|
|
IL287617B2
(en)
|
2019-05-09 |
2024-11-01 |
Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
CA3143196A1
(en)
|
2019-06-12 |
2020-12-17 |
The Wistar Institute |
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
EP4162036A1
(en)
|
2020-06-09 |
2023-04-12 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
EP4216949A4
(en)
|
2020-09-28 |
2024-12-11 |
Yale University |
Selective agonists of 5-ht2a receptor and methods of use
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
IL318658A
(en)
|
2022-07-29 |
2025-03-01 |
Sanifit Therapeutics S A |
IP4-4,6-Substituted Derivative Compounds for Use in the Treatment, Inhibition of Progression, and Prevention of Ectopic Calcification
|
|
IL319372A
(en)
|
2022-09-06 |
2025-05-01 |
Hadasit Med Res Service |
Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
|
|
EP4658242A1
(en)
|
2023-02-03 |
2025-12-10 |
Tris Pharma, Inc. |
Low sodium oxybate once nightly composition
|
|
WO2025037248A1
(en)
|
2023-08-14 |
2025-02-20 |
Neurim Pharmaceuticals (1991) Ltd. |
Gal475 compositions and methods of use thereof
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|
|
WO2026050206A1
(en)
|
2024-08-27 |
2026-03-05 |
Ironwood Pharmaceuticals, Inc. |
Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
|